GB2160201B
(en)
|
1984-06-14 |
1988-05-11 |
Wyeth John & Brother Ltd |
Quinazoline and cinnoline derivatives
|
US5123951A
(en)
|
1986-03-31 |
1992-06-23 |
Rhone-Poulenc Nederland B.V. |
Synergistic plant growth regulator compositions
|
JPS646261A
(en)
|
1987-03-31 |
1989-01-10 |
Nisshin Flour Milling Co |
4-thioquinazoline derivative, its production and antiulcer agent containing said derivative as active component
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
US5034393A
(en)
|
1989-07-27 |
1991-07-23 |
Dowelanco |
Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
|
US5238951A
(en)
|
1991-02-01 |
1993-08-24 |
E. R. Squibb & Sons, Inc. |
Heterocyclic amido prostaglandin analogs
|
DE4114733A1
(de)
|
1991-05-06 |
1992-11-12 |
Huels Chemische Werke Ag |
Verfahren zur herstellung von substituierten malonesteraniliden und malonsaeure-monoaniliden
|
US5480883A
(en)
|
1991-05-10 |
1996-01-02 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
US5710158A
(en)
|
1991-05-10 |
1998-01-20 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
US6057344A
(en)
|
1991-11-26 |
2000-05-02 |
Sepracor, Inc. |
Methods for treating hypertension, and angina using optically pure (-) amlodipine
|
US6498144B1
(en)
|
1993-10-18 |
2002-12-24 |
North Shore - Long Island Jewish Research Institute |
Use of scatter factor to enhance angiogenesis
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
GB9510757D0
(en)
|
1994-09-19 |
1995-07-19 |
Wellcome Found |
Therapeuticaly active compounds
|
TW321649B
(fr)
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
ES2203642T3
(es)
|
1995-06-07 |
2004-04-16 |
Pfizer Inc. |
Derivados de pirimidina heterociclicos con anillos condensados.
|
EP0832073B1
(fr)
|
1995-06-07 |
2002-01-16 |
Sugen, Inc. |
Quinazolines et compositions pharmaceutiques
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
GB9514265D0
(en)
|
1995-07-13 |
1995-09-13 |
Wellcome Found |
Hetrocyclic compounds
|
JP4009681B2
(ja)
|
1995-11-07 |
2007-11-21 |
キリンファーマ株式会社 |
血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
NZ325248A
(en)
|
1995-12-23 |
1999-09-29 |
Pfizer Res & Dev |
Quinoline and quinazoline compounds useful in therapy
|
BR9707495A
(pt)
|
1996-02-13 |
1999-07-27 |
Zeneca Ltd |
Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
KR100489174B1
(ko)
|
1996-03-05 |
2005-09-30 |
제네카-파마 소시에떼아노님 |
4-아닐리노퀴나졸린유도체
|
WO1997034876A1
(fr)
|
1996-03-15 |
1997-09-25 |
Zeneca Limited |
Derives de cinnoline et leur emploi comme medicaments
|
US6107300A
(en)
|
1996-03-27 |
2000-08-22 |
Dupont Pharmaceuticals |
Arylamino fused pyrimidines
|
SI0892789T2
(sl)
|
1996-04-12 |
2010-03-31 |
Warner Lambert Co |
Ireverzibilni inhibitorji tirozin kinaz
|
ID19609A
(id)
|
1996-07-13 |
1998-07-23 |
Glaxo Group Ltd |
Senyawa-senyawa heterosiklik
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
US5962407A
(en)
|
1996-07-26 |
1999-10-05 |
Kelly; Michael T. |
Loloatin derivatives and analogs
|
KR100567649B1
(ko)
|
1996-09-25 |
2006-04-05 |
아스트라제네카 유케이 리미티드 |
혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
CN1169795C
(zh)
|
1996-10-01 |
2004-10-06 |
协和发酵工业株式会社 |
环胺取代的含氮杂环化合物及其组合物
|
GB9700504D0
(en)
|
1997-01-11 |
1997-02-26 |
Pfizer Ltd |
Pharmaceutical compounds
|
GB9705361D0
(en)
|
1997-03-14 |
1997-04-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
WO1998047873A1
(fr)
|
1997-04-18 |
1998-10-29 |
Kirin Beer Kabushiki Kaisha |
Procede de production de derives de quinolone
|
KR20000069311A
(ko)
|
1997-04-22 |
2000-11-25 |
디르크 반테 |
Crf 길항성 퀴노- 및 퀴나졸린
|
GB9708917D0
(en)
|
1997-05-01 |
1997-06-25 |
Pfizer Ltd |
Compounds useful in therapy
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
EP1005470B1
(fr)
|
1997-08-22 |
2007-08-01 |
AstraZeneca AB |
Derives d'oxindolylquinazoline utiles comme inhibiteurs d'angiogenese
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
WO1999061428A1
(fr)
|
1998-05-28 |
1999-12-02 |
Parker Hughes Institute |
Utilisation des quinazolines pour le traitement de tumeurs cerebrales
|
JP4516690B2
(ja)
|
1998-08-11 |
2010-08-04 |
ノバルティス アーゲー |
血管形成阻害活性を有するイソキノリン誘導体
|
US6313129B1
(en)
|
1998-08-21 |
2001-11-06 |
Hughes Institute |
Therapeutic compounds
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
JP5170486B2
(ja)
|
1998-09-10 |
2013-03-27 |
バイオイコール ア−ゲー |
局所適用性産物
|
AU763669B2
(en)
|
1998-09-29 |
2003-07-31 |
Wyeth Holdings Corporation |
Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
EP1117653B1
(fr)
|
1998-10-01 |
2003-02-05 |
AstraZeneca AB |
Derives quinoline et quinazoline et leur utilisation comme inhibiteurs de maladies dans lesquelles la cytokine intervient
|
FR2784030B1
(fr)
|
1998-10-02 |
2002-12-20 |
Inst Nat Sante Rech Med |
Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine
|
JP2002527436A
(ja)
|
1998-10-08 |
2002-08-27 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体
|
JP3687900B2
(ja)
|
1998-11-19 |
2005-08-24 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
チロシンキナーゼの不可逆的阻害剤であるn−[4−(3−クロロ−4−フルオロフェニルアミノ)−7−(3−モルホリン−4−イルプロポキシ)キナゾリン−6−イル]アクリルアミド
|
WO2000043366A1
(fr)
|
1999-01-22 |
2000-07-27 |
Kirin Beer Kabushiki Kaisha |
Derives de quinoline et derives de quinazoline
|
PL199802B1
(pl)
|
1999-02-10 |
2008-10-31 |
Astrazeneca Ab |
Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania
|
GB9904103D0
(en)
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
US6080747A
(en)
|
1999-03-05 |
2000-06-27 |
Hughes Institute |
JAK-3 inhibitors for treating allergic disorders
|
DE19911509A1
(de)
|
1999-03-15 |
2000-09-21 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US6258820B1
(en)
|
1999-03-19 |
2001-07-10 |
Parker Hughes Institute |
Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
|
JP2002539262A
(ja)
|
1999-03-19 |
2002-11-19 |
パーカー ヒューズ インスティテュート |
キナゾリン化合物製剤および治療におけるその使用
|
RS49836B
(sr)
|
1999-03-31 |
2008-08-07 |
Pfizer Products Inc., |
Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
|
EP1169041A2
(fr)
|
1999-03-31 |
2002-01-09 |
The Procter & Gamble Company |
Utilisation de derives d'acide carbamic pour traiter les infections virales
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9910577D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
US6126917A
(en)
|
1999-06-01 |
2000-10-03 |
Hadasit Medical Research Services And Development Ltd. |
Epidermal growth factor receptor binding compounds for positron emission tomography
|
CA2375259C
(fr)
|
1999-06-21 |
2009-04-28 |
Boehringer Ingelheim Pharma Kg |
Heterocycles bicycliques, medicaments contenant lesdits composes, leur utilisation et procedes permettant de les preparer
|
RU2002110461A
(ru)
|
1999-09-21 |
2004-03-10 |
Астразенека Аб (Se) |
Производные хиназолина и их применение в качестве фармацевтических веществ
|
GB9922171D0
(en)
|
1999-09-21 |
1999-11-17 |
Zeneca Ltd |
Chemical compounds
|
US6759410B1
(en)
|
1999-11-23 |
2004-07-06 |
Smithline Beecham Corporation |
3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
|
AU4903201A
(en)
|
1999-11-30 |
2001-07-03 |
Parker Hughes Institute |
Inhibitors of thrombin induced platelet aggregation
|
US20020002169A1
(en)
|
1999-12-08 |
2002-01-03 |
Griffin John H. |
Protein kinase inhibitors
|
TWI281915B
(en)
|
1999-12-24 |
2007-06-01 |
Kirin Brewery |
Quinoline and quinazoline derivatives and drugs containing the same
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
WO2001055116A2
(fr)
|
2000-01-28 |
2001-08-02 |
Astrazeneca Ab |
Composes chimiques
|
US6664390B2
(en)
|
2000-02-02 |
2003-12-16 |
Warner-Lambert Company Llc |
Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine
|
AU2001236698A1
(en)
|
2000-02-07 |
2001-08-14 |
Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft |
2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
|
ES2290117T3
(es)
|
2000-02-15 |
2008-02-16 |
Sugen, Inc. |
Inhibidores de proteina quinasa 2-indolina sustituida con pirrol.
|
AU4545201A
(en)
|
2000-03-13 |
2001-09-24 |
American Cyanamid Co |
Method of treating or inhibiting colonic polyps
|
US6608048B2
(en)
|
2000-03-28 |
2003-08-19 |
Wyeth Holdings |
Tricyclic protein kinase inhibitors
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
US6627634B2
(en)
|
2000-04-08 |
2003-09-30 |
Boehringer Ingelheim Pharma Kg |
Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
GEP20063831B
(en)
|
2000-06-22 |
2006-05-25 |
Pfizer Prod Inc |
Substituted bicyclic derivatives for treatment of abnormal cell growth
|
US6919338B2
(en)
|
2000-06-28 |
2005-07-19 |
Astrazeneca Ab |
Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase
|
EP1174118A1
(fr)
|
2000-06-28 |
2002-01-23 |
Cognis France S.A. |
Utilisation de l'inuline et de dérivés de celui-ci
|
FR2811658B1
(fr)
|
2000-07-17 |
2004-07-02 |
Cfpi Nufarm |
Reacteur biologique a lit fixe immerge et procede de traitement d'effluents liquides
|
JP2002030083A
(ja)
*
|
2000-07-18 |
2002-01-29 |
Kirin Brewery Co Ltd |
N−(2−クロロ−4−{[6−メトキシ−7−(3−ピリジルメトキシ)−4−キノリル]オキシ}フェニル)−n’−プロピルウレアの二塩酸塩
|
CA2417500C
(fr)
|
2000-07-28 |
2008-11-18 |
Georgetown University Medical Center |
Inhibiteur de l'erbb-2 kinase selectif de petites molecules
|
WO2002016352A1
(fr)
|
2000-08-21 |
2002-02-28 |
Astrazeneca Ab |
Derives de quinazoline
|
FR2813307B1
(fr)
|
2000-08-23 |
2002-11-08 |
Sanofi Synthelabo |
Aminoalkenylbenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation et les compositions les contenant
|
US6403580B1
(en)
|
2000-08-26 |
2002-06-11 |
Boehringer Ingelheim Pharma Kg |
Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
DE10042058A1
(de)
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US6740651B2
(en)
|
2000-08-26 |
2004-05-25 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
US6653305B2
(en)
|
2000-08-26 |
2003-11-25 |
Boehringer Ingelheim Pharma Kg |
Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
|
US6656946B2
(en)
|
2000-08-26 |
2003-12-02 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
US6617329B2
(en)
|
2000-08-26 |
2003-09-09 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines and their use as medicaments
|
US6849625B2
(en)
|
2000-10-13 |
2005-02-01 |
Astrazeneca Ab |
Quinazoline derivatives with anti-tumour activity
|
EP1326860A1
(fr)
|
2000-10-13 |
2003-07-16 |
AstraZeneca AB |
D riv s de quinazoline
|
DE60134679D1
(de)
|
2000-10-20 |
2008-08-14 |
Eisai R&D Man Co Ltd |
Stickstoff enthaltende aromatische Heterozyklen
|
EP1332141A1
(fr)
|
2000-10-25 |
2003-08-06 |
AstraZeneca AB |
Derives de quinazoline
|
AU2002212697A1
(en)
|
2000-11-02 |
2002-05-15 |
Nippon Shinyaku Co. Ltd. |
Quinazoline derivatives and drugs
|
WO2002036570A1
(fr)
|
2000-11-02 |
2002-05-10 |
Astrazeneca Ab |
Quinoleines 4 substitues en position 4 utilisees comme agents antitumoraux
|
US7067532B2
(en)
|
2000-11-02 |
2006-06-27 |
Astrazeneca |
Substituted quinolines as antitumor agents
|
US7019012B2
(en)
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
US6900220B2
(en)
|
2001-01-02 |
2005-05-31 |
Syntex (U.S.A.) Llc |
Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
|
GB0103046D0
(en)
|
2001-02-07 |
2001-03-21 |
Novartis Ag |
Organic Compounds
|
JP2002265365A
(ja)
|
2001-03-08 |
2002-09-18 |
Koyo Chemical Kk |
好中球機能抑制剤
|
JP4307843B2
(ja)
|
2001-04-19 |
2009-08-05 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体
|
KR100879669B1
(ko)
|
2001-04-27 |
2009-01-21 |
기린 파마 가부시끼가이샤 |
아졸릴기를 갖는 퀴놀린 유도체 및 퀴나졸린 유도체
|
SE0101675D0
(sv)
|
2001-05-11 |
2001-05-11 |
Astrazeneca Ab |
Novel composition
|
WO2002092579A1
(fr)
|
2001-05-14 |
2002-11-21 |
Astrazeneca Ab |
Derives de 4-anilinoquinazoline
|
WO2002092577A1
(fr)
|
2001-05-14 |
2002-11-21 |
Astrazeneca Ab |
Derives quinazoliniques
|
WO2002092578A1
(fr)
|
2001-05-14 |
2002-11-21 |
Astrazeneca Ab |
Derives de quinazoline
|
US6734303B2
(en)
|
2001-05-18 |
2004-05-11 |
Pfizer Inc. |
Process for the production of quinazolines
|
DE10125432A1
(de)
|
2001-05-25 |
2002-11-28 |
Bayer Ag |
Substituierte Benzoylketone
|
AU2002350105A1
(en)
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel quinazolines and uses thereof
|
DE60233736D1
(de)
|
2001-06-22 |
2009-10-29 |
Kirin Pharma K K |
Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
|
KR100397792B1
(ko)
|
2001-06-28 |
2003-09-13 |
한국과학기술연구원 |
4-(페닐아미노)-[1,4]디옥사노[2,3-g]퀴나졸린 유도체 및그의 제조방법
|
GB0118752D0
(en)
|
2001-08-01 |
2001-09-26 |
Pfizer Ltd |
Process for the production of quinazolines
|
US7229774B2
(en)
|
2001-08-02 |
2007-06-12 |
Regents Of The University Of Michigan |
Expression profile of prostate cancer
|
EP3168218B1
(fr)
|
2001-08-15 |
2018-11-14 |
Pharmacia & Upjohn Company LLC |
Un cristal comprenant un sel d'acide malique de n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide pour utilisation comme un médicament
|
US20030066060A1
(en)
|
2001-09-28 |
2003-04-03 |
Ford Richard L. |
Cross profile guided optimization of program execution
|
EP1447405A4
(fr)
|
2001-10-17 |
2005-01-12 |
Kirin Brewery |
Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
|
US7169788B2
(en)
|
2001-10-30 |
2007-01-30 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
GB0126433D0
(en)
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
US7319107B2
(en)
|
2001-11-08 |
2008-01-15 |
Johnson & Johnson Consumer Companies, Inc. |
1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
|
GB0128108D0
(en)
|
2001-11-23 |
2002-01-16 |
Astrazeneca Ab |
Therapeutic use
|
CA2467573A1
(fr)
|
2001-11-27 |
2003-06-19 |
Wyeth Holdings Corporation |
3-cyanoquinolines en tant qu'inhibiteurs de kinases egf-r et her2
|
WO2003047584A1
(fr)
|
2001-12-05 |
2003-06-12 |
Astrazeneca Ab |
Derives de la quinoline
|
GB0129099D0
(en)
|
2001-12-05 |
2002-01-23 |
Astrazeneca Ab |
Chemical compounds
|
AU2002347336A1
(en)
|
2001-12-05 |
2003-06-17 |
Astrazeneca Ab |
Quinoline derivatives
|
CA2469730A1
(fr)
|
2001-12-10 |
2003-06-19 |
Aryx Therapeutics |
Nouveaux composes pour le traitement de l'arythmie cardiaque, synthese et methodes d'utilisation desdits composes
|
HUP0402662A2
(hu)
|
2001-12-12 |
2005-05-30 |
Pfizer Products Inc. |
Az E-2-metoxi-N-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]kinazolin-6-il}-allil)acetamid sói, előállításuk és rák elleni alkalmazásuk
|
AP2004003058A0
(en)
|
2001-12-12 |
2004-06-30 |
Pfizer Prod Inc |
Quinazoline derivatives for the treatment of abnormal cell growth.
|
WO2003055866A1
(fr)
|
2001-12-21 |
2003-07-10 |
Bayer Pharmaceuticals Corporation |
Composes derives de quinazoline et de quinoline servant d'inhibiteurs de prolylpeptidase, d'inducteurs d'apoptose et d'agents therapeutiques anticancereux
|
TW200301123A
(en)
|
2001-12-21 |
2003-07-01 |
Astrazeneca Uk Ltd |
New use
|
UA82058C2
(uk)
|
2001-12-24 |
2008-03-11 |
Астразенека Аб |
Заміщені похідні хіназоліну як інгібітори ауроракінази, спосіб їх одержання, фармацевтична композиція на їх основі
|
WO2003064431A2
(fr)
|
2002-01-29 |
2003-08-07 |
Glaxo Group Limited |
Composes aminopiperidine, leur procede de preparation et compositions pharmaceutiques les contenant
|
WO2003064421A1
(fr)
|
2002-01-29 |
2003-08-07 |
Glaxo Group Limited |
Derives aminopiperidine
|
AU2003202094B2
(en)
|
2002-02-01 |
2009-10-08 |
Astrazeneca Ab |
Quinazoline compounds
|
DE10204462A1
(de)
|
2002-02-05 |
2003-08-07 |
Boehringer Ingelheim Pharma |
Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
|
TWI324597B
(en)
|
2002-03-28 |
2010-05-11 |
Astrazeneca Ab |
Quinazoline derivatives
|
DE10217689A1
(de)
|
2002-04-19 |
2003-11-13 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
|
US6693198B2
(en)
|
2002-04-22 |
2004-02-17 |
Xanthus Life Sciences, Inc. |
Amonafide salts
|
EP1535910A4
(fr)
|
2002-05-01 |
2007-03-14 |
Kirin Brewery |
Derives de quinoleine et derives de quinazoline inhibiteurs de l'autophosphorylation du recepteur du facteur stimulant la proliferation des macrophages
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
AU2003249212C1
(en)
|
2002-07-15 |
2011-10-27 |
Symphony Evolution, Inc. |
Receptor-type kinase modulators and methods of use
|
US7560558B2
(en)
|
2002-08-23 |
2009-07-14 |
Kirin Beer Kabushiki Kaisha |
Compound having TGFβ inhibitory activity and medicinal composition containing the same
|
GB0219746D0
(en)
|
2002-08-23 |
2002-10-02 |
Inst Of Ex Botany Ascr |
Azapurine derivatives
|
US7419984B2
(en)
|
2002-10-17 |
2008-09-02 |
Cell Therapeutics, Inc. |
Pyrimidines and uses thereof
|
EP1559715B1
(fr)
|
2002-10-21 |
2007-09-26 |
Kirin Beer Kabushiki Kaisha |
Sel de n- {2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl} -n'-(5-methyl-3-isoxazolyl)uree sous forme cristalline
|
EP1566379A4
(fr)
|
2002-10-29 |
2005-11-09 |
Kirin Brewery |
DERIVES DE QUINOLINE ET DE QUINAZOLINE INHIBANT L'AUTOPHOSPHORYLATION DE Flt3 ET COMPOSITIONS MEDICALES LES CONTENANT
|
PT1562955E
(pt)
|
2002-11-04 |
2008-05-05 |
Astrazeneca Ab |
Derivados de quinazolina como inibidores da scr tirosina-cinase
|
US7432275B2
(en)
|
2002-12-13 |
2008-10-07 |
Neurogen Corporation |
Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
|
CN1729001A
(zh)
|
2002-12-18 |
2006-02-01 |
辉瑞产品公司 |
用于治疗异常细胞生长的4-苯胺基喹唑啉衍生物
|
AU2003299943A1
(en)
|
2002-12-23 |
2004-07-22 |
Ariad Pharmaceuticals, Inc. |
Heterocycles and uses thereof
|
AU2003292838A1
(en)
|
2002-12-27 |
2004-07-29 |
Kirin Beer Kabushiki Kaisha |
Therapeutic agent for wet age-related macular degeneration
|
US8176532B1
(en)
|
2003-03-17 |
2012-05-08 |
Sprint Communications Company L.P. |
Secure access point for scada devices
|
AU2004221812B2
(en)
|
2003-03-19 |
2010-02-18 |
Exelixis Inc. |
Tie-2 modulators and methods of use
|
KR100559180B1
(ko)
|
2003-05-20 |
2006-03-14 |
김민서 |
조건부 거래에 따른 전자결제 방법 및 전자결제 서버
|
WO2005003140A1
(fr)
|
2003-07-02 |
2005-01-13 |
Pharmacia & Upjohn Company Llc |
4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides utilises comme agents antiviraux
|
EP1641759B1
(fr)
|
2003-07-07 |
2014-03-12 |
Merck Patent GmbH |
Derives de malonamide
|
JP4299090B2
(ja)
*
|
2003-09-24 |
2009-07-22 |
株式会社東海理化電機製作所 |
車両用空調装置の操作装置
|
ES2371383T3
(es)
|
2003-09-26 |
2011-12-30 |
Exelixis, Inc. |
N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer.
|
WO2005046589A2
(fr)
|
2003-11-07 |
2005-05-26 |
Chiron Corporation |
Sels de composes de quinolinone acceptables d'un point de vue pharmaceutique et presentant des proprietes pharmaceutiques ameliorees
|
CA2543650C
(fr)
|
2003-12-25 |
2010-10-26 |
Eisai Co., Ltd. |
Crystaux de sel de 4-(3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide ou de ses solvate, et leur procede de production
|
AU2005207946A1
(en)
|
2004-01-23 |
2005-08-11 |
Amgen Inc. |
Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
|
MY144177A
(en)
|
2004-02-04 |
2011-08-15 |
Novartis Ag |
Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide.
|
WO2005089353A2
(fr)
|
2004-03-16 |
2005-09-29 |
Sepracor Inc. |
(s)-amlodipine malate
|
US7173031B2
(en)
|
2004-06-28 |
2007-02-06 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
CA2572331A1
(fr)
*
|
2004-07-02 |
2006-02-09 |
Exelixis, Inc. |
Modulateurs de c-met et leur methode d'utilisation
|
JP2008537784A
(ja)
*
|
2005-03-04 |
2008-09-25 |
カラーリンク・インコーポレイテッド |
4パネル表示システム
|
CA2603748A1
(fr)
|
2005-04-06 |
2006-10-12 |
Exelixis, Inc. |
Modulateurs c-met modulators et procedes d'utilisation
|
WO2007062135A2
(fr)
|
2005-11-23 |
2007-05-31 |
Junji Shiraishi |
Procede assiste par ordinateur permettant la detection des modifications d'intervalles dans des scintigrammes successifs des os du corps entier ainsi que progiciels et systemes associes
|
WO2007102074A2
(fr)
|
2006-03-07 |
2007-09-13 |
Cadila Healthcare Limited |
Sels de quetiapine
|
BRPI0708615A2
(pt)
|
2006-03-07 |
2011-06-07 |
Array Biopharma Inc |
compostos de pirazol heterobicìclicos e métodos de uso
|
US20080027223A1
(en)
|
2006-03-23 |
2008-01-31 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of eszopiclone malate
|
US20080004273A1
(en)
|
2006-05-30 |
2008-01-03 |
Stephane Raeppel |
Inhibitors of protein tyrosine kinase activity
|
ES2375284T3
(es)
|
2006-08-23 |
2012-02-28 |
Eisai R&D Management Co., Ltd. |
Sal de un derivado de fenoxipiridina, o cristal de la misma, y procedimiento de producción de la misma.
|
WO2008070616A2
(fr)
|
2006-12-01 |
2008-06-12 |
University Of Utah Research Foundation |
Procédés et compositions liés au hif-1a
|
CA2671982C
(fr)
|
2006-12-14 |
2016-01-26 |
Exelixis, Inc. |
Procedes d'utilisation d'inhibiteurs de mek
|
WO2008083319A1
(fr)
|
2006-12-29 |
2008-07-10 |
Il Yang Pharmaceutical Company, Ltd. |
Formes à l'état solide de l'ilaprazole de pureté énantiomérique
|
WO2009085972A1
(fr)
|
2007-12-19 |
2009-07-09 |
Sepracor Inc. |
Sels de maléate, de bésylate et de l-malate de 6-(5-chloro-2-pyridyl)-5-[(4-méthyl-1-pipérazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]-pyrazine
|
UY31800A
(es)
|
2008-05-05 |
2009-11-10 |
Smithkline Beckman Corp |
Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
|
TW201035017A
(en)
|
2008-09-26 |
2010-10-01 |
Smithkline Beecham Corp |
Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide
|
AU2009300328A1
(en)
|
2008-10-01 |
2010-04-08 |
Ludwig Institute For Cancer Research |
Methods for the treatment of cancer
|
JP5486606B2
(ja)
|
2008-11-13 |
2014-05-07 |
エクセリクシス, インク. |
キノリン誘導体の調製方法
|
US20130030172A1
(en)
|
2008-12-04 |
2013-01-31 |
Exelixis, Inc. |
Methods of Preparing Quinoline Derivatives
|
CN110818633A
(zh)
|
2009-01-16 |
2020-02-21 |
埃克塞里艾克西斯公司 |
一种苹果酸盐及其晶型
|
WO2011009095A1
(fr)
|
2009-07-17 |
2011-01-20 |
Exelixis, Inc. |
Formes cristallines du n‑[3‑fluoro-4-({méthyloxy)-7-[(3-morpholin-4-yl- propyl)oxy]quinoléin-4-yl}oxy)phényl]-n'-(4-fluorophényl)cyclopropane- 1,1-dicarboxamide
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
EP2475390A4
(fr)
|
2009-09-09 |
2014-01-01 |
Quintiles Transnat Corp |
Méthodes et compositions pour le traitement de maladies ou troubles à médiation par le récepteur tyrosine kinase
|
EP2545038A1
(fr)
|
2010-03-12 |
2013-01-16 |
Exelixis, Inc. |
Forme cristaline hydratée du n-[3-fluoro-4-({6-(méthyloxy)-7-[(3- morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phényl]-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide
|
US20120070368A1
(en)
|
2010-04-16 |
2012-03-22 |
Exelixis, Inc. |
Methods of Using C-Met Modulators
|
EP4014971A1
(fr)
|
2010-07-16 |
2022-06-22 |
Exelixis, Inc. |
Compositions pharmaceutiques modulatrices de c-met
|
CA2826751C
(fr)
|
2011-02-10 |
2021-05-18 |
Exelixis, Inc. |
Procedes de synthese de quinoleines et compositions pharmaceutiques les incluant
|
US20120252840A1
(en)
|
2011-04-04 |
2012-10-04 |
Exelixis, Inc. |
Method of Treating Cancer
|
EA201490676A1
(ru)
|
2011-09-22 |
2015-02-27 |
Экселиксис, Инк. |
Способ лечения остеопороза
|
WO2013166296A1
(fr)
|
2012-05-02 |
2013-11-07 |
Exelixis, Inc. |
Double modulateur met-vegf pour traiter des métastases osseuses ostéolytiques
|
CN104703600A
(zh)
|
2012-09-07 |
2015-06-10 |
埃克塞里艾克西斯公司 |
用于治疗肺腺癌的met、vegfr和ret的抑制剂
|
JP2016515628A
(ja)
|
2013-04-04 |
2016-05-30 |
エグゼリクシス, インコーポレイテッド |
癌を治療するための複合薬
|
CN106255499A
(zh)
|
2014-03-17 |
2016-12-21 |
埃克塞里艾克西斯公司 |
卡博替尼制剂的给药
|